10-Q quarterly report · filed Nov 5, 2026

Cogent Biosciences, Inc. (COGT) Q3 2026 10-Q Quarterly Report

Short answer

Cogent Biosciences, Inc. (COGT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$111M
−37.7% YoY · −15.6% QoQ
EPS (diluted)
−$0.60
−20.0% YoY · −15.4% QoQ

Source: XBRL data from the Cogent Biosciences, Inc. (COGT) Q3 2026 10-Q on SEC EDGAR. USD.

Cogent Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, no product sales; net loss $111.4M vs $80.9M YoY
  • Operating margin not applicable, operating loss $117.2M vs $83.4M YoY
  • R&D expense $75.1M, G&A $42.1M, versus $69.0M and $14.4M YoY
  • Cash, equivalents and securities $791.1M; operating cash outflow $244.9M for nine months
  • U.S. launch targeted second half 2026, pending approval; liquidity expected through late 2028

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors filed February 17, 2026
  • Carried-forward risks may materially adversely affect business, financial condition, or operating results
  • Additional unknown or currently immaterial risks could materially affect results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Cogent Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.